KRAS and familial pancreatic carcinoma: SIRT5 has been proven to be involved in tumorigenesis and drug resistance in many cancers [28, 30, 51–53], but opposite tumor-suppressor roles have also been found in various tumor treatment models, including liver cancer [54], Kras-induced pancreatic cancer [30], renal cell carcinoma [27], and acute promyelocytic leukemia [55].